Modeling atrial fibrosis in vitro—Generation and characterization of a novel human atrial fibroblast cell line

Stephan R. Künzel1, Johanna S. E. Rausch1, Charlotte Schäffer1, Maximilian Hoffmann1, Karolina Künzel1, Erik Klapproth1, Theresa Kant1, Natalie Herzog2, Jan-Heiner Küpper2, Kristina Lorenz3,4, Svenja Dudek5,6, Ramona Emig5,6, Ursula Ravens5,6, Eva A. Rog-Zielinska5,6, Rémi Peyronnet5,6 and Ali El-Armouche1

1 Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
2 Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany
3 Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany
4 Leibniz-Institut für Analytische Wissenschaften – ISAS e. V., Dortmund, Germany
5 Institut für Experimentelle Kardiovaskuläre Medizin, Universitäts Herzcentrum, Freiburg Bad - Krozingen, Freiburg im Breisgau, Germany
6 Faculty of Medicine, University of Freiburg, Freiburg, Germany

Keywords
cardiovascular disease; cell culture; cell lines; fibroblasts; fibrosis; heart

Correspondence
S. R. Künzel and A. El-Armouche, Institute of Pharmacology and Toxicology, Technische Universität Dresden, Faculty of Medicine Carl Gustav Carus, Fiedlerstraße 42, 01309 Dresden, Germany
Fax: 0049 351 4586315
Tel: 0049 351 4586278; 0049 351 4586255
E-mails: stephan.kuenzel@tu-dresden.de (SRK); ali.el-armouche@tu-dresden.de (AE-A)

Stephan R. Künzel and Johanna S. E. Rausch contributed equally

(Received 5 March 2020, revised 7 May 2020, accepted 14 May 2020)
doi:10.1002/2211-5463.12896

Cardiovascular diseases (CVD) such as heart failure and arrhythmia represent the leading cause of death worldwide [1,2]. A well-recognized concomitant of CVD is cardiac fibrosis [1], which is the structural manifestation of an imbalance in extracellular matrix (ECM) homeostasis. With nearly 45% of all deaths in the Western world attributable to fibroproliferative disease, the clinical relevance of fibrotic remodeling is enormous [3,4]. This is particularly true in the case of atrial fibrosis, associated with a detrimental clinical outcome of highly abundant supraventricular arrhythmias like atrial fibrillation (AF) [5]. However, due to

Atrial fibrillation (AF) is regularly accompanied by cardiac fibrosis and concomitant heart failure. Due to the heterogeneous nature and complexity of fibrosis, the knowledge about the underlying mechanisms is limited, which prevents effective pharmacotherapy. A deeper understanding of cardiac fibroblasts is essential to meet this need. We previously described phenotypic and functional differences between atrial fibroblasts from patients in sinus rhythm and with AF. Herein, we established and characterized a novel human atrial fibroblast line, which displays typical fibroblast morpholgy and function comparable to primary cells but with improved proliferation capacity and low spontaneous myofibroblast differentiation. These traits make our model suitable for the study of fibrosis mechanisms and for drug screening aimed at developing effective antifibrotic pharmacotherapy.

Abbreviations
AF, atrial fibrillation; CVD, cardiovascular diseases; ECM, extracellular matrix; HAF, human atrial fibroblast; HVF, human ventricular fibroblast; PAF, primary atrial fibroblast; SR, sinus rhythm.
the heterogeneous nature and complexity of the pro-
fibrotic processes, the mechanistic knowledge is limited. 
For this reason, effective antifibrotic pharmacotherapy 
is still elusive [6].

The key cellular mediators of cardiac fibrosis are 
fibroblasts [7,8]. In the healthy heart, fibroblasts regu-
late ECM homeostasis by secretion and degradation of 
ECM components thereby safeguarding the mechanical 
integrity of the myocardium. Furthermore, fibroblasts 
have been shown to play regulatory roles in cardiac 
electrophysiology and inflammation processes [9]. 
Upon activation by pathological stimuli like myocar-
dial injury or arrhythmia, fibroblasts undergo a pheno-
typical and functional transition toward myofibro-
blasts [10]. Once activated, myofibroblasts increase in 
size, commence expression of orderly arranged fila-
ments of alpha-smooth muscle actin (\(\alpha\)SMA), and 
become highly secretory, resulting in enhanced deposi-
tion of interstitial collagen as well as local enrichment 
of cytokines and other mediators of inflammation [11].

Although this process is initially beneficial for wound 
healing, a prolonged presence of myofibroblasts is 
detrimental for physiological cardiac function [12].

Fibroblast cultures have become invaluable models 
for the study of fibrosis mechanisms in vitro [13] for 
derivation of novel targeted therapy strategies. How-
ever, human atrial fibroblast (HAF) cell lines are scar-
cely available and primary human fibroblasts are 
difficult to obtain on a regular basis for medical and 
ethical reasons. Thus, the objectives of our study were 
(a) to generate and to characterize a new model of 
HAFs to investigate atrial fibrosis mechanisms and 
(b) to highlight the intracardial phenotypic heteroge-
neity between atrial and ventricular fibroblast models.

Materials and methods

Informed consent

All patients participating in this study wrote informed 
consent according to the Declaration of Helsinki 
(file number of the institutional review committee: EK 
114082202). The collection and study of human samples 
in Freiburg were reviewed and approved by the Ethics Com-
mision of the University of Freiburg, Freiburg, Germany 
(reference: 393/16: 214/18).

Cell acquisition and culture conditions

An immortalized human ventricular fibroblast cell line 
(HVF) was purchased from ABM Inc. (Richmond, BC, 
Canada). Cardiac right atrial tissue biopsies were obtained 
during open-heart surgery in cooperation with Herzzentrum 
Dresden GmbH. Primary HAFs (PAF) were isolated from 
the tissue biopsies via outgrowth as described previously 
[10]. Fibroblasts were cultured on noncoated NUNC cell 
culture flasks in DMEM (10% FCS, 1% penicillin–strepto-
mycin) at 37 °C and 5% CO₂.

Lentiviral transfer of proliferation genes

By lentiviral transfer of Upcyte® proliferation genes [14,15] 
(Invitrogen, Karlsruhe, Germany) into primary atrial 
fibroblasts (PAF) of a male donor, we generated the non-
transformed HAF cell line (HAF-SRK01) with extended 
lifespan and proliferation competence. The donor was 
selected among available candidates based on adequate 
health (see Table 1 for donor characteristics).

Functional fibroblast characterization

Experiments to determine fibroblast proliferation, sponta-
neous myofibroblast differentiation, and wound healing 
capacity (migration) were performed as described previ-
ously [10].

Proliferation

Cells were seeded on 12-well plates at densities of \(1 \times 10^4\) 
well. Cells were harvested and counted after 7 and 14 days 
using 0.25 % trypsin and a Burker counting chamber.

Myofibroblast differentiation and immunocytochemistry

Myofibroblast differentiation was assessed with immuno-
cytochemical staining for \(\alpha\)SMA in fibroblasts grown on glass 
coverslips. A cell was considered a myofibroblast when 
orderly arranged \(\alpha\)SMA microfilaments were present 
(Figs 1 and 4C). A minimum of 50 cells/ coverslip was ana-
lyzed. The primary and secondary antibodies used for 
immunocytochemistry (ICC) are provided below (Table 2).

Migration

To evaluate fibroblast migration capacity, a commercially 
available wound healing assay was performed (Cell Biolabs,

Table 1. Donor characteristics.

| Item                  | Value |
|-----------------------|-------|
| Age (Years)           | 83    |
| Sex                   | Male  |
| BMI (kg·m⁻²)          | 30.8  |
| Grade of heart failure| NYHA 2 |
| Ejection fraction (%)  | 60    |
| Hypertension          | Yes   |
| Diabetes mellitus     | No    |
BIOCAT GMBH, Heidelberg, Germany) according to the manufacturer’s instructions.

**Collagen secretion and deposition**

Soluble collagen secretion was determined in culture medium using a colorimetric hydroxyproline assay kit (Sigma-Aldrich, St. Louis, Missouri, USA) according to the manufacturer’s instructions. Collagen deposition on the growth surface was visualized using ICC against collagen Iα1. In order to facilitate collagen production, the medium was supplemented with 0.5 mM L-Ascorbic Acid (AAcid) [16]. AAcid is a necessary cofactor for prolyl and lysyl hydroxylases, enzymes essential for the collagen biosynthesis. Cells were cultured for 6 days.

---

**Table 2. Antibodies.**

| Antibody           | Dilution | Conjugate/ Source | Lot-Nr.  | Application |
|--------------------|----------|-------------------|----------|-------------|
| GAPDH              | 1 : 1000 | Mouse             | sc-365062| WB          |
| DDR2               | 1 : 200  | Mouse             | MAB25381 | ICC         |
| Vimentin           | 1 : 200  | Rabbit            | #5741    | ICC         |
| αSMA               | 1 : 200 (ICC) | Mouse       | A5228    | ICC/ WB     |
| Collagen 1         | 1 : 200  | Rabbit            | ab34710  | ICC         |
| Collagen Iα1       | 1 : 100  | Goat              | MyBioSource | ICC       |
| SMAD2/3            | 1 : 1.000| Rabbit            | #3102    | WB          |
| PhosphoSMAD2/3     | 1 : 1.000| Rabbit            | #8828    | WB          |
| Anti-mouse         | 1 : 10 000| Peroxidase      | A3682    | WB          |
| Anti-rabbit        | 1 : 10 000| Peroxidase      | 11-035-045| WB         |
| Alexa Fluor 546 (anti-mouse) | 1 : 400 | Streptavidin    | Z25004   | ICC         |
| Alexa Fluor 546 (anti-rabbit) | 1 : 400 | Streptavidin    | Z25304   | ICC         |
| Alexa Fluor 555 (anti-goat)  | 1 : 500  | Rabbit           | ab150146 | ICC         |
Cell stiffness

The effective Young’s modulus, $E_{\text{Eff}}$, was assessed using the Chiaro nanoindenter system (Optics11, Amsterdam, Netherlands) as described previously [17]. Briefly, a spherical tip with 3 µm radius, attached to a calibrated cantilever with a spring constant of 0.014 N m$^{-1}$, is used to indent the sample while the bending of the cantilever is tracked by interferometry. The force required for sample indentation was calculated as the product of cantilever bending and spring constant, and the effective Young’s modulus ($E_{\text{Eff}}$) was derived using the Hertzian model for contact mechanics [18] under the assumption of Poisson’s ratio of 0.5 for incompressible materials, which is commonly used for mechanical testing of cells and tissue [19]. Throughout this manuscript, $E_{\text{Eff}}$ is referred to as stiffness. On each cell, indentations were performed at three different positions, excluding the nuclear region. Prior to stiffness measurements, cells were cultured on CyPhyGels for 4 days. These are hydrogels based on polyethylene glycol and the cyanobacterial photoreceptor Cph1* [Cph1-Y263F (amino acids 1–514)] allowing modulation of gel stiffness between 3 and 6 kPa by light [17,20].

Statistics

Statistical analysis and graphic representation of the data were done with GRAPHPAD PRISM software (version 5, GraphPad Software, San Diego, CA, USA). Data are presented as mean ± SEM. Differences between two groups were compared using Student’s t-test with Welch’s correction. Differences between multiple groups were compared with one-way ANOVA with Newman–Keuls post-test. $P$-values < 0.05 were considered statistically significant.

Results and Discussion

The scientific value of primary human cells is undisputable although their availability is limited due to ethical and medical reasons. Cell lines have therefore been well established as a valuable alternative. In contrast to primary cells, cell lines do not display interpatient variability due to donor age, medication, or morbidities and theoretically provide an almost unlimited quantity of material. These features are particularly attractive to study cardiac pathomechanisms, since cardiovascular-patient-derived primary cells typically display high variability [22]. For this reason, we generated a novel cell culture model of the less commonly available atrial fibroblast subtype to study cardiac fibrosis mechanisms in vitro. Subsequently, the newly developed cell line ‘HAF-SRK01’ was functionally characterized and compared to PAF and commercially available HVF.

In brightfield microscopy, HVFs, HAFs, and PAFs displayed the typical stellar fibroblast shape without notable morphological differences between the groups.

![Fig. 2](image-url) Functional analysis of cardiac fibroblast subtypes. (A) Proliferation curves of HVFs ($n = 6$), HAFs ($n = 7$) and PAFs ($n = 21$). Cells were cultured in DMEM (10% FCS, 1% penicillin-streptomycin) at 37 °C, 5% CO₂, and counted after 7 and 14 days. (B) Quantification of immunostaining experiments for fibrillary αSMA protein abundance ($n_{\text{HVF}} = 4$, $n_{\text{HAF}} = 7$, $n_{\text{PAF}} = 6$). (C) Basal 24-h migration capacity of HVFs ($n = 5$), HAFs ($n = 5$), and PAFs ($n = 6$). Data are presented as mean ± SEM. Differences between multiple groups were compared with one-way ANOVA with Newman–Keuls post-test. *$P < 0.05$. **$P < 0.01$. ***$P < 0.001$; n.s., not significant.
All cells expressed the accepted fibroblast marker proteins [11] vimentin, discoid domain receptor 2 (DDR2), and collagen 1 confirming their fibroblast phenotype (Fig. 1). Only the expression of the myofibroblast marker αSMA varied distinctly between the groups (quantification provided in Fig. 2B).

Proliferation and myofibroblast differentiation are essential fibroblast properties that are important for the study of fibrosis mechanisms. Therefore, these parameters were analyzed and compared in HVFs, HAFs, and PAFs. Cell proliferation was strikingly different between the three groups (Fig. 2A). PAFs proliferated at the lowest rate, followed by intermediately proliferating HVFs. The newly generated HAFs displayed the highest proliferation rate (20-fold increase in cell number compared to day 0). Likewise, spontaneous myofibroblast differentiation as determined by the presence of fibrillary αSMA myofilaments in immunofluorescence assays differed between the groups. HVFs and HAFs displayed comparably low spontaneous differentiation (<15% of total cells), whereas PAF cultures consisted of ~50% myofibroblasts (Fig. 2B). These results point at an inverse correlation of proliferation and myofibroblast differentiation which is consistent with the hypothesis that myofibroblasts are terminally differentiated cells [23,24] and as such cease to proliferate. These results support recent findings suggesting that fibroblast differentiation rather than proliferation is crucial for fibrosis development [25]. A possible reason for the high spontaneous differentiation and resulting low proliferation rates in PAFs could be patient-specific imprinting [26] due to donor age, medication, or comorbidities. Epigenetic regulation of proliferation-relevant genes was shown to affect functional properties of isolated cells [27,28]. The finding of, for example, aberrant methylation patterns in fibroblasts from AF patients compared to control samples reinforces

![Image](image_url)

**Fig. 3.** Adaption of HAF and PAF stiffness in response to different stiffness of the growth matrix. (A) HAFs present a typical fibroblast morphology when grown on CyPhyGels. Nuclei were stained with Hoechst (blue), F-actin was stained with Phalloidin (red), and αSMA was stained in green. The scale bar equals 20 µm. (B) Representative force/indentation curves used to calculate the stiffness (E_eff) of individual cells cultured on either stiff (black curve) or soft gels (grey curve). The force required to indent a cell on the stiff substrate is higher than on the soft substrate. (C) Measurements of HAF and PAF stiffness on soft (~2.7 kPa) and stiff (~4.6 kPa) CyPhyGels (36 ≤ n ≤ 57). Data are presented as mean ± SEM. Differences between multiple groups were compared with one-way ANOVA with Newman–Keuls post-test. ***P < 0.001.

![Diagram](diagram_url)

**Fig. 4.** Induction of a cellular fibrosis phenotype in HAFs with TGF-β. (A) Protein expression of phosphorylated SMAD2/3 after 72 h of TGF-β stimulation (1, 3, 10 ng·mL⁻¹) in HAFs (n = 3 per concentration) and representative original WB below. (B) Protein expression of αSMA after 72 h of TGF-β stimulation (1, 3, 10 ng·mL⁻¹) in HAFs (n = 3 per concentration) and representative original WB below. (C) Quantification of fibroblasts positive for fibrillary αSMA microfilaments after stimulation with 10 ng·mL⁻¹ TGF-β for 72 h and representative immunofluorescence staining of fibrillary αSMA upon TGF-β stimulation. The scale bars equal 50 µm. (D) Soluble collagen secretion (left) and representative immunofluorescence image for deposited Collagen Ix1 (right) by HAFs upon stimulation with 10 ng·mL⁻¹ TGF-β (n = 14 vs. 10). The scale bars equal 50 µm. (E) Proliferation curves of HAFs under control conditions (n = 4) and upon stimulation with 10 ng·mL⁻¹ TGF-β (n = 4). Cells were counted after 7 and 14 days. (F) 24-h migration capacity of HAFs under control conditions (n = 6) and upon stimulation with 10 ng·mL⁻¹ TGF-β (n = 4). Data are presented as mean ± SEM. Differences between two groups were compared using Student’s t-test with Welch’s correction. Differences between multiple groups were compared with one-way ANOVA with Newman–Keuls post-test. *P < 0.05. **P < 0.01. ***P < 0.001.
A novel fibroblast line to model atrial fibrosis

**Figure A**

- Graph showing the phosphorylation of SMAD 2/3 protein abundance with different concentrations of TGF-β (1 ng/ml, 3 ng/ml, 10 ng/ml).
- Significant differences are indicated by asterisks: ***.

**Figure B**

- Graph showing the αSMA protein abundance with different concentrations of TGF-β (1 ng/ml, 3 ng/ml, 10 ng/ml).
- Significant differences are indicated by asterisks: *, **.

**Figure C**

- Bar graph showing the percentage of fibroblasts expressing αSMA.
- Significant differences are indicated by asterisks: ***.

**Figure D**

- Graph showing collagen secretion with TGF-β treatment.
- Significant differences are indicated by asterisk: *.

**Figure E**

- Graph showing cell count over days of culture with control and 10 ng/ml TGF-β.
- Significant differences are indicated by asterisks: *, ***.

**Figure F**

- Graph showing migration of HAFs in 24 hours with control and TGF-β treatment.
- Significant difference is indicated by asterisk: *.
A novel fibroblast line to model atrial fibrosis

S. R. Künzel et al.

this assumption [21] and stresses the value of adequate cell lines matching the scientific question.

Fibroblast migration to areas of myocardial tissue damage is important for wound healing and fibrosis development in the heart [29,30]. We compared the migration capacity of HVFs, HAFs, and PAFs with an in vitro wound healing assay [10]. HVFs migrated to the smallest extent followed by HAFs. PAFs displayed the highest migration capacity among the tested cell populations (Fig. 2C). It has been shown that myofibroblasts—once activated—stimulate fibroblast migration via chemotactic signals in auto- and paracrine manner [31]. This finding is reflected in the here presented results of the migration and differentiation analysis. The cultures with low myofibroblast content (HVFs and HAFs) displayed lower migration rates than PAF cultures, which consisted of ~ 50% of myofibroblasts (Fig. 2B).

An essential feature of fibroblasts is their ability to adapt to the stiffness of their growth matrix. This capability is particularly relevant in the context of fibrosis which leads to a strong increase of tissue stiffness [32,33]. Stiffening of the growth matrix is well-known to contribute to the activation of fibroblasts into myofibroblasts and leads to remodeling (stiffening) of the cytoskeleton [17]. We investigated whether HAFs’ response to differences in the stiffness of the growth matrix is preserved by using hydrogels whose stiffness can be controlled by light. HAFs were cultured on CyPhyGels for 4 days (Fig. 3A). Their stiffness was significantly increased on stiff gels compared to soft gels (Fig. 3B, C). HAF stiffness on soft and stiff gels was not different from that of PAFs indicating that the two cell types show comparable adaptations to differences in their mechanical environment (Fig. 3B).

One key mechanism in fibrosis development is the activation of the TGF-β-SMAD pathway [34]. TGF-β is considered the master regulator of fibroblast activation and fibrosis [35]. It is therefore important that a novel in vitro fibroblast model responds adequately to stimulation with TGF-β. We exposed the HAF-SRK01 cell line to TGF-β in ascending concentrations (1, 3, 10 ng·mL⁻¹) for 72 h. HAFs responded to TGF-β with a concentration-dependent increase in SMAD2/3 phosphorylation and concomitant increase in αSMA protein expression (Fig. 4A, B) as determined by WB [36]. Immunofluorescence revealed the increased presence of fibrillary αSMA myofilaments confirming myofibroblast differentiation (Fig. 4C). Furthermore, we investigated collagen secretion, which is the crucial step of structural ECM remodeling and fibrosis development. HAFs responded with increased collagen secretion and deposition in response to TGF-β stimulation (Fig. 4D). Finally, we investigated the effects of TGF-β on HAF proliferation and migration. We found significantly reduced fibroblast proliferation after 14 days (Fig. 4E) and significantly increased cell migration (Fig. 4F). These results are consistent with the hypothesis that myofibroblasts proliferate less but show increased migration capacity [23,24]. Taken together, these results demonstrate the functionality of the cell line as an in vitro fibrosis model as it is able to recapitulate the essential cellular steps and mechanisms in the development of fibrosis.

There are limitations to the current study, which should be addressed in future research on this topic. Since we had only limited access to atrial appendage samples from control (sinus rhythm) patients, the group size of some experiments depending on PAFs is limited. It must also be considered that control fibroblasts do not originate from healthy donors since the patients had to undergo cardiac surgery as well. Despite these limitations, we are convinced that our newly generated cell line is a valuable addition to the existing spectrum of methods for cardiac fibrosis research.

With low basal myofibroblast differentiation, high proliferation and migration rates and conserved mechano-sensing (adaptation to their mechanical environment), our newly generated HAF cell line HAF-SRK01 can serve as a robust in vitro model to improve the understanding of atrial fibrosis mechanisms. This model can effectively complement research on PAFs, as it is continuously available on a large scale due to high proliferation rates, making its use more flexible and most importantly independent of patient or animal sample acquisition. Moreover, our study emphasizes that cardiac fibroblast subtypes are phenotypically heterogeneous with distinct functional differences depending on their ventricular or atrial origin. Analyzing the proliferative, migratory, and spontaneous myofibroblast differentiation capacity, we show that patient-specific variations have a major influence on the results obtained with primary cells. Accordingly, PAFs displayed the highest basal myofibroblast differentiation stressing the fact that the proper choice of a fibroblast model is critical to avoid misinterpretations, as the causes of variability, for example, in myofibroblast differentiation (e.g., donor medication and comorbidities) cannot always be determined retrospectively. Even though cell lines have limitations on their own, they offer the advantage of more consistent results due to the lack of patient-related variability. This and the fact that no common cell line
model of atrial fibroblasts currently exists make the HAF-SRK01 line particularly interesting for mechanistic questions and screening experiments. We expect that our new HAF cell line will become an increasingly useful model to study fibrosis in vitro, as there is an urgent need for effective antifibrotic pharmacotherapy, especially in the context of AF. Improved understanding of atrial fibrosis mechanisms will open up new opportunities for disease modeling and chamber-specific drug screening.

Acknowledgement

We would like to thank ‘Deutsche Herzstiftung’ for providing the ‘Kaltenbach Promotionstipendium’ to Johanna Rausch and Charlotte Schäffer. We would also like to thank Ms. Manja Newe, B.Sc., Ms. Romy Kempe, and Mrs. Annett Opitz for their expert technical support.

This work was supported by the Förderkreis Dresden Herz-Kreislauf-Tage e.V. (to SRK); the ‘MeDD-IV’ (to SRK) of the Faculty of Medicine Carl Gustav Carus Dresden, Germany; a research grant of the Ministry of Science, Research and Arts Baden-Württemberg (MWK-BW Sonderlinie Medizin, #3091311631); and a DFG Emmy Noether Fellowship (to EARZ, #396913060). Open Access Funding by the Publication Fund of the TU Dresden.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

SRK conceived and supervised the study. SRK, EK, AEA, KL, UR, JSER, EARZ, and RP designed experiments. JSER, KK, CS, MH, TK, SD, RE, EARZ, and RP performed experiments. NH and JHK immortalized primary donor cells. SRK wrote the manuscript and all authors revised and improved the manuscript. Parts of SRK’s, JSER’s, MH’s, and CS’s doctoral theses are included in this study.

References

1. Hinderer S and Schenke-Layland K (2019) Cardiac fibrosis – A short review of causes and therapeutic strategies. Adv Drug Deliv Rev 146, 77–82.
2. Murtha LA, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW, Burgess JK, Knight DA and Boyle AJ (2017) The processes and mechanisms of cardiac and pulmonary fibrosis. Front Physiol 8, 777.
3. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214, 199–210.
4. Artlett CM (2012) The role of the NLRP3 inflammasome in fibrosis. Open Rheumatol J 6, 80–86.
5. Jalife J and Kaur K (2015) Atrial remodeling, fibrosis, and atrial fibrillation. Trend Cardiovasc Med 25, 475–484.
6. Fang L, Murphy AJ and Dart AM (2017) A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol 8, 186.
7. Baum J and Duffy HS (2011) Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol 57, 376–379.
8. Tallquist MD and Molkentin JD (2017) Redefining the identity of cardiac fibroblasts. Nat Rev Cardiol 14, 484–491.
9. Rog-Zielinska EA, Norris RA, Kohl P and Markwald R (2016) The living scar-cardiac fibroblasts and the injured heart. Trends Mol Med 22, 99–114.
10. Poulet C, Künzel S, Böttner E, Lindner D, Westermann D and Ravens U (2016) Altered physiological functions and ion currents in atrial fibroblasts from patients with chronic atrial fibrillation. Physiol Rep 4, e12681.
11. Ivey MJ and Tallquist MD (2016) Defining the cardiac fibroblast. Circ J 80, 2269–2276.
12. Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W et al. (2019) Targeting cardiac fibrosis with engineered T cells. Nature 573, 430–433.
13. Künzel SR, Schaeffer C, Sekeres K, Mehner CS, Schacht Wall SM, Newe M, Kämmerer S and El-Armouche A (2019) Ultrasonic-augmented primary adult fibroblast isolation. J Vis Exp (149), e59858. http://doi.org/10.3791/59858.
14. Herzog N, Hansen M, Mietzbauer S, Schmidtke K-U, Anderer U, Lupp A, Sperling S, Seehofer D, Damm G, Scheibner K et al. (2016) Primary-like human hepatocytes genetically engineered to obtain proliferation competence display hepatic differentiation characteristics in monolayer and organotypical spheroid cultures. Cell Biol Int 40, 341–353.
15. Burkard A, Dänh C, Heinz S, Zutavern A, Sonntag-Buck V, Maltman D, Przyborski S, Hewitt NJ and Braspenning J (2012) Generation of proliferating human hepatocytes using Upcyte® technology: characterisation and applications in induction and cytotoxicity assays. Xenobiotica 42, 939–956.
16. Hata R and Senoo H (1989) L-ascorbic acid 2-phosphate stimulates collagen accumulation, cell proliferation, and formation of a three-dimensional tissue-like substance by skin fibroblasts. J Cell Physiol 138, 8–16.
17. Emig R, Zgerski-Johnston CM, Beyersdorf F, Rylski B, Ravens U, Weber W, Kohl P, Hörner M and Peyronnet R (2019) Human atrial fibroblast adaptation...
to heterogeneities in substrate stiffness. *Front Physiol* 10, 1526.
18 Hertz H (1882) Ueber die Berührung fester elastischer Körper. *J Die Reine Angewandte Math* 92, 156–171.
19 Guz N, Dokukin M, Kalaparthi V and Sokolov I (2014) If cell mechanics can be described by elastic modulus: study of different models and probes used in indentation experiments. *Biophys J* 107, 564–575.
20 Hörner M, Raute K, Hummel B, Madl J, Creusen G, Thomas OS, Christen EH, Hotz N, Gübeli RJ, Engesser R et al. (2019) Phytochrome-based extracellular matrix with reversibly tunable mechanical properties. *Adv Mater* Weinheim 31, e1806727.
21 Kuenzel SR, Sekeres K, Kaemmerer S, Kolanowski T, Meyer-Roxlau S, Piorkowski C, Tugtekin SM, Rose-John S, Yin X, Mayr M et al. (2018) Hypoxia-induced epigenetic silencing of polo-like kinase 2 promotes fibrosis in atrial fibrillation. *bioRxiv* 445098.
22 Rahimi K, Lam CSP and Steinhubl S (2018) Cardiovascular disease and multimorbidity: a call for interdisciplinary research and personalized cardiovascular care. *PLoS Med* 15, e1002545.
23 Hecker L, Jagirdar R, Jin T and Thannickal VJ (2011) Reversible differentiation of myofibroblasts by MyoD. *Exp Cell Res* 317, 1914–1921.
24 Evans RA, Tian YC, Steadman R and Phillips AO (2003) TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. *Exp Cell Res* 282, 90–100.
25 Scruggs AM, Koh HB, Tripathi P, Leeper NJ, White ES and Huang SK (2018) Loss of CDKN2B promotes fibrosis via increased fibroblast differentiation rather than proliferation. *Am J Respir Cell Mol Biol* 59, 200–214.
26 Ferguson-Smith AC (2011) Genomic imprinting: the emergence of an epigenetic paradigm. *Nat Rev Genet* 12, 565–575.
27 Bechtel W, McGooihan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller R, Kalluri R and Zeisberg M (2010) Methylation determines fibroblast activation and fibrogenesis in the kidney. *Nat Med* 16, 544–550.
28 Benetatos L, Dasoula A, Hatzimichael E, Syed N, Youkelatou M, Dramitsaris G, Bourantas KL and Crook T (2011) Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. *Ann Hematol* 90, 1037–1045.
29 Raizman JE, Komiljenovic J, Chang R, Deng C, Bedosky KM, Rattan SG, Cunnington RH, Freed DH and Dixon IMC (2007) The participation of the Na+-Ca2+ exchanger in primary cardiac myofibroblast migration, contraction, and proliferation. *J Cell Physiol* 213, 540–551.
30 Yano T, Miura T, Ikeda Y, Matsuda E, Saito K, Miki T, Kobayashi H, Nishino Y, Ohtani S and Shimamoto K (2005) Intracardiac fibroblasts, but not bone marrow derived cells, are the origin of myofibroblasts in myocardial infarct repair. *Cardiovasc Pathol* 14, 241–246.
31 Leeb SN, Vogl D, Falk W, Schölmerich J, Rogler G and Gelbmann CM (2002) Regulation of migration of human colonic myofibroblasts. *Growth Factors* 20, 81–91.
32 Herum KM, Lunde IG, McCulloch AD and Christensen G (2017) The Soft- and hard-heartedness of cardiac fibroblasts: mechanotransduction signaling pathways in fibrosis of the Heart. *J Clin Med* 6, 53.
33 Hinz B (2013) Matrix mechanics and regulation of the fibroblast phenotype. *Periodontol 2000* 63, 14–28.
34 Walton KL, Johnson KE and Harrison CA (2017) Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis. *Front Pharmacol* 8, 461.
35 Meng X, Nikolic-Paterson DJ and Lan HY (2016) TGF-β: the master regulator of fibrosis. *Nat Rev Nephrol* 12, 325–338.
36 El-Armouche A, Wittkörper K, Degenhardt F, Weinberger F, Didié M, Melnychenko I, Grimm M, Peeck M, Zimmermann WH, Unsöld B et al. (2008) Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. *Cardiovasc Res* 80, 396–406.